A single dose of the Oxford vaccine could reduce transmission of the virus by two thirds, according to a new study.

The data from the study by the University of Oxford, which has not yet been peer reviewed, supports the four to 12-week prime-boost dosing interval that the UK’s regulator recommends.

READ MORE: How close to Bucks is the South African variant of Covid-19?

Researchers said that the first dose of the Oxford/AstraZeneca jab offers protection of 76% up to three months and may reduce transmission by 67% – with efficacy rising to 82.4% after the second dose 12 weeks later.

Before these results, little was known about how effective the Covid-19 vaccines were at preventing transmission of the disease.

The findings indicate that those who have been vaccinated are not only protected from the disease, but that they are not likely to pass on the virus to anyone.

It also suggests the vaccine eliminates severe illness, as none of those in the study were admitted to hospital with coronavirus.

Slough Observer: How the Oxford vaccine works. (PA)How the Oxford vaccine works. (PA)

Health Secretary Matt Hancock said: “This is a hugely encouraging study and further reinforces our confidence that vaccines are capable of reducing transmission and protecting people from this awful disease.

“This report shows the Oxford vaccine works and works well.”

Prime Minister Boris Johnson said the data from the study was “really encouraging”.

READ MORE: Matt Hancock slams 'pathetic' TikTok user targeting Chris Whitty in the street

Professor Andrew Pollard, chief investigator of the Oxford Vaccine Trial – and study co-author, said: “These new data provide an important verification of the interim data that was used by more than 25 regulators including the MHRA (Medicines and Healthcare products Regulatory Agency) and EMA (European Medicines Agency) to grant the vaccine emergency use authorisation.

“It also supports the policy recommendation made by the Joint Committee on Vaccination and Immunisation (JCVI) for a 12-week prime-boost interval, as they look for the optimal approach to roll out, and reassures us that people are protected from 22 days after a single dose of the vaccine.”